<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610359</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1451</org_study_id>
    <nct_id>NCT04610359</nct_id>
  </id_info>
  <brief_title>Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis</brief_title>
  <official_title>Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis; Open-labelled, Single Center, Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MIRAE CELL BIO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study primarily aimed to evaluate the safety of human embryonic stem cell (hESC)-derived&#xD;
      mesenchyma stem cells in interstitial cystitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>One month after stem cell injection</time_frame>
    <description>Any TEAEs reported by patients or assessed by laboratory and image work up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Three months after stem cell injection</time_frame>
    <description>Any TEAEs reported by patients or assessed by laboratory and image work up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Six months after stem cell injection</time_frame>
    <description>Any TEAEs reported by patients or assessed by laboratory and image work up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Nine months after stem cell injection</time_frame>
    <description>Any TEAEs reported by patients or assessed by laboratory and image work up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Twelve months after stem cell injection</time_frame>
    <description>Any TEAEs reported by patients or assessed by laboratory and image work up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of pain after stem cell injection</measure>
    <time_frame>Changes of Pain from baseline, 1, 3, 6, and 12 months after stem cell injection</time_frame>
    <description>Assessed by VAS (Visual Analog Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of PUF (Pelvic Pain and Urgency/Frequency) scores after stem cell injection</measure>
    <time_frame>Changes of PUF score from baseline, 1, 3, 6, 12 months after stem cell injection</time_frame>
    <description>Assessed by PUF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of ICQ (O'Leary-Sant interstitial cystitis symptom index/problem index) scores after stem cell injection</measure>
    <time_frame>Changes of ICQ scores from baseline, 1, 3, 6, 12 months after stem cell injection</time_frame>
    <description>Assessed by ICQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of voiding profiles after stem cell injection</measure>
    <time_frame>Changes of voiding profiles from baseline, 1, 3, 6, 12 months after stem cell injection</time_frame>
    <description>Assessed by voiding diary (frequency, nocturia, urgency, urge incontinence and mean voided volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Hunner lesion after stem cell injection</measure>
    <time_frame>Changes of Hunner lesion from baseline, 1, 3, 6, 12 months after stem cell injection</time_frame>
    <description>Assessed by cystoscopy (number, sized, location)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Stem Cell Transplant</condition>
  <condition>Mesenchymal Stem Cell</condition>
  <arm_group>
    <arm_group_label>Stem cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interstitial cystitis patients who receive submucosal injection of hESC-MSCs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR-MC-01</intervention_name>
    <description>Submucosal injection of 2.0 x 10,000,000/5ml (1mL * 5 sites)</description>
    <arm_group_label>Stem cell group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, aged &gt;= 20 years&#xD;
&#xD;
          -  Interstitial cystitis symptom duration more than 6 months&#xD;
&#xD;
          -  Presence of Hunner lesions in outpatient cystoscopy (within one months of screening),&#xD;
             with size &lt; 2cm, number &lt;= 2&#xD;
&#xD;
          -  VAS (Visual pain analogue scale) &gt;=4 in screening symptom questionnaire&#xD;
&#xD;
          -  Those who are suitable for stem cell transplantation&#xD;
&#xD;
               -  normal laboratory findings (hematological, chemical)&#xD;
&#xD;
               -  no history of drug abuse&#xD;
&#xD;
               -  negative HIV, HBV, HCV serology tests&#xD;
&#xD;
               -  No history of malignancies&#xD;
&#xD;
               -  willing to contraception&#xD;
&#xD;
               -  no plan for blood, tissue donation&#xD;
&#xD;
          -  Who can understand consent form and willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recurrent urinary tract infection ( more than twice per past six months or more than&#xD;
             three times per past one year) or active urinary tract infection&#xD;
&#xD;
          -  any active or past history of tuberculosis or systemic infection&#xD;
&#xD;
          -  Anatomical abnormality of lower urinary tract&#xD;
&#xD;
          -  History of following procedures&#xD;
&#xD;
               -  stem cell transplantation In past 6 months,&#xD;
&#xD;
               -  transurethral resection/fulguration of Hunner lesion or hydrodistension of&#xD;
                  bladder&#xD;
&#xD;
               -  intravesical instillation of ialuril&#xD;
&#xD;
               -  hysterectomy, anti-incontinence surgery, transvaginal surgery, pelvic organ&#xD;
                  prolapse repair, vagina delivery or C/sec&#xD;
&#xD;
               -  any neurological conditions including cerebrovascular disease, multiple&#xD;
                  sclerosis, spinal cord injury, Parkinson disease&#xD;
&#xD;
               -  indwelling Foley catheter or intermittent catheterization&#xD;
&#xD;
               -  any plans for electrostimulation, neuromodulation, physiotherapy or operation for&#xD;
                  other organs&#xD;
&#xD;
               -  any history of malignancy&#xD;
&#xD;
               -  history of myocardiac infarction in past 12 months&#xD;
&#xD;
               -  Uncontrolled diabetes (HbAlc &gt;= 7.2%) or diabetes requiring insulin injection&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic &gt;170mmHg or &lt;90mmHg, diastolic &gt;100mmHg or&#xD;
                  &lt;50mmHg)&#xD;
&#xD;
               -  Immunodeficiency&#xD;
&#xD;
               -  Positive HBV, HCV, HIV, syphilis&#xD;
&#xD;
               -  pregnant or on breast feeding&#xD;
&#xD;
               -  any history of drug, alcohol abuse. mis-use&#xD;
&#xD;
               -  Any significant signs, symptoms or previous diagnosis of psychological disorder&#xD;
&#xD;
               -  Impossible to follow scheduled visits&#xD;
&#xD;
               -  Currently participating or participated in other clinical studies within past 3&#xD;
                  months&#xD;
&#xD;
               -  Allergic to protein products (serum), antibiotics (gentamicin), DMSO (Dimethyl&#xD;
                  sulfoxide)&#xD;
&#xD;
               -  Any circumstances that is not suitable for participating or continuing clinical&#xD;
                  study or participants who clinical investigator considers not suitable for&#xD;
                  participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Soo Choo, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung-Soo Choo, M.D, Ph.D</last_name>
    <phone>+82230103735</phone>
    <email>mschoo@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Soo Choo, professor</last_name>
      <phone>82-2-3010-3735</phone>
      <email>mschoo@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Soo Choo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

